The Manufacturers Life Insurance Company raised its stake in Sanofi (NASDAQ:SNY - Free Report) by 122.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 356,058 shares of the company's stock after acquiring an additional 195,719 shares during the quarter. The Manufacturers Life Insurance Company's holdings in Sanofi were worth $17,180,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in SNY. Invesco Ltd. grew its position in Sanofi by 3.5% in the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock worth $581,619,000 after purchasing an additional 408,752 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after buying an additional 5,091,304 shares during the period. Boston Partners lifted its stake in shares of Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after purchasing an additional 2,501,073 shares during the period. Franklin Resources Inc. grew its position in Sanofi by 10.8% during the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock valued at $182,164,000 after purchasing an additional 369,530 shares during the last quarter. Finally, Magnetar Financial LLC boosted its stake in shares of Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock worth $161,103,000 after buying an additional 1,705,148 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.
Sanofi Price Performance
Shares of Sanofi stock traded down $1.44 on Tuesday, hitting $53.15. The company had a trading volume of 3,507,793 shares, compared to its average volume of 2,357,653. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The business has a 50-day simple moving average of $54.51 and a 200-day simple moving average of $52.04. The company has a market cap of $134.27 billion, a PE ratio of 21.35, a PEG ratio of 1.01 and a beta of 0.55. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The company had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the firm posted $1.78 earnings per share. The company's revenue for the quarter was down 11.0% compared to the same quarter last year. Research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.
Sanofi Increases Dividend
The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a $2.0369 dividend. The ex-dividend date is Friday, May 9th. This represents a dividend yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio is currently 57.14%.
Wall Street Analyst Weigh In
SNY has been the topic of several analyst reports. BNP Paribas began coverage on Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective on the stock. Finally, Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three analysts have rated the stock with a hold rating, two have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Sanofi presently has an average rating of "Buy" and a consensus target price of $63.33.
Get Our Latest Report on SNY
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Read More
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
